Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms

European Journal of Biochemistry

Volumn 268, Issue 23, 2001, Pages 6274-6283

  Hansen, Martin ^a   Busse, Marta N ^a   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Cancer; Extracellular proteolysis; Fibrinolysis; Proteinase inhibitors; Serine proteinases

Indexed keywords

AMINO ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

ALPHA HELIX; AMINO ACID COMPOSITION; ARTICLE; BIOCHEMISTRY; CANCER; CARDIOVASCULAR DISEASE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; HYDROGEN BOND; LATENT PERIOD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; PROTEIN TARGETING;

AMINO ACID SUBSTITUTION; AMINO ACIDS; BINDING SITES; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; URINARY PLASMINOGEN ACTIVATOR; VARIATION (GENETICS); VITRONECTIN;

EID: 0035210951     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0014-2956.2001.02582.x     Document Type: Article

References (52)

1. 1-antitrypsin for structure and function of serpins
2. The biostructural pathology of the serpins: Critical function of sheet opening mechanism
3. Phylogeny of the serpin superfamily: Implications of patterns of amino acid conservation for structure and function
4. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates
5. The inhibition mechanism of serpins
6. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor
7. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism
8. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70Å and full insertion of the reactive center loop into β-sheet A
9. The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites
10. Structure of a serpin-protease complex shows inhibition by deformation
11. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism
12. Partitioning of serpin-proteinase reactions between stable inhibition and substrate cleavage is regulated by the rate of serpin reactive center loop insertion into β-sheet A
13. Structural basis of latency in plasminogen activator inhibitor-1
14. Serpin tertiary structure transformation
15. The crystal structure of plasminogen activator inhibitor 2 at 2.0Å resolution: Implications for serpin function
16. What do dysfunctional serpins tell us about molecular mobility and disease?
17. Familial dementia caused by polymerization of mutant neuroserpin
18. Molecular evolution of plasminogen activator inhibitor-1 functional stability
19. Engineering of conformations of plasminogen activator inhibitor-1. A crucial role of b-strand 5A residues in the transition of active form to latent and substrate forms
20. Conformational changes of the reactive-centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasmino-gen-activator inhibitor 1
21. Solvent effects on activity and conformation of plasminogen activator inhibitor-1
22. Vitronectin and substitution of a β-strand 5A lysine residue potentiate activity-neutralization of PA inhibitor-1 by monoclonal antibodies against a-helix F
23. Role of Lys335 in the metastability and function of inhibitory serpins
24. 1-antitrypsin
25. Structure of vitronectin and its biological role in haemostasis
26. The PAI-1/vitronectin interaction: Two cats in a bag?
27. Plasminogen activator inhibitor type-1: Reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing
28. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system
29. Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies
30. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor
31. Monoclonal antibody to human 66,000 molecular wieght plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification
32. Localisation of epitopes of monoclonal anti-urokinase-type plasminogen activator antibodies. Relationship to antibody effects on molecular interactions of the enzyme
33. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling
34. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation
35. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator
36. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate
37. Modulation of plasminogen activator inhibitor 1 by Triton X-100-identification of two consecutive conformational transitions
38. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1
39. Extending the capabilities of targeted molecular dynamics: Simulation of a large conformational transition in plasminogen activator inhibitor 1
40. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1
41. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1
42. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion
43. Localization of vitronectin binding domain in plasminogen activator inhibitor-1
44. Structures of active and latent PAI-1: A possible stabilizing role for chloride ions
45. Fibrinolysis and risk of coronary artery disease
46. The urokinase-type plasminogen activator system in cancer metastasis: A review
47. The plasminogen activation system in tumor growth, invasion, and metastasis
48. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: Identification of two different mechanisms
49. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagen-esis
50. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits
51. Epitope mapping for four monoclonal antibodies against human plasminogen activator inhibitor type-1: Implications for antibody-mediated PAI-1-neutralization and vitronectin-binding
52. A regulatory hydrophobic area in the flexible joint region of plasminogen activator inhibitor-1, defined with fluorescent activity-neutralizing ligands. Ligand-induced serpin polymerization